Burning Rock and Dizal Reports China's NMPA Approval of Co-Developed Companion Diagnostic (CDx) for Lung Cancer
Shots:
- Burning Rock and Dizal announced NMPA approval for the co-developed CDx (LungCure CDx) for Sunvozertinib for EGFR exon 20 insertion mutation (exon20ins) mutations in NSCLC patients
- The approval corresponds to the simultaneous independent development of LungCure CDx (NGS-based CDx) by Burning Rock and Dizal's Sunvozertinib, an EGFR exon20ins targeted therapy
- LungCure CDx enables in vitro detection of various mutation statuses of EGFR, MET, ERBB2, KRAS, BRAF, PIK3CA, ALK, ROS1, and RET genes for NSCLC patients, including point mutations, insertions/deletions, fusions, and amplifications
Ref: Burning Rock | Image: Burning Rock
Related News:- The NMPA Clears Shanghai Henlius’ IND Application of HLX17 (Biosimilar, Keytuda) for Treating Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
An avid reader and a dedicated learner, Prince works as a Content Writer at PharmaShots. Prince possesses an exceptional quality of breaking down the barriers of words by simplifying the terms in digestible chunks to make content readable and comprehensible. Prince likes to read books and loves to spend his free time learning and upskilling himself.
